Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunotherapy to Treat Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Advanced prostate cancer~* At least 1 bone metastasis~* Testosterone \< 50 ng/dl~* Prior treatment with docetaxel~Exclusion Criteria:~* Brain metastasis~* Autoimmune disease~* Known HIV, Hep B, or Hep C infection~* More than 2 prior systemic anticancer regimens for prostate cancer~* Prior treatment on BMS CA180227 for prostate cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).